Target intelligence / Profile preview

C12orf42 antisense RNA 1 (C12orf42-AS1)

Target: C12orf42-AS1
Molecular classification: Long non-coding RNA (lncRNA), Antisense RNA, Other (not protein, not an enzyme, not a receptor, etc.)

Overview

C12orf42 antisense RNA 1 (C12orf42-AS1) is a long non-coding antisense RNA gene located on chromosome 12 (chr12:103151824-103179247, hg38)[1]. It is transcribed from the opposite strand of the C12orf42 gene locus and classified as a non-coding RNA. While many antisense RNAs play roles in regulating gene expression via cis or trans interactions, epigenetic modulation, and transcriptional interference, there is currently no experimental evidence specifying the biological function, disease relevance, or drug interactions of C12orf42-AS1[1][4][6]. The locus and sequence are cataloged, but functional features remain uncharacterized; it is not a recognized therapeutic target, receptor, or enzyme.

Other names: C12orf42-AS1

Mechanism of action

Not applicable. Antisense RNAs may generally act by recruiting epigenetic complexes, blocking transcription, or targeting complementary RNAs for degradation[2], but no evidence exists for drug mechanism specific to C12orf42-AS1.

Biological functions

Antisense RNA molecules may regulate gene expression of neighboring or overlapping protein-coding genes through transcriptional interference or epigenetic modifications[2][6].Possible involvement in *cis-* and *trans-* gene regulation, influencing transcription, chromatin structure, and RNA stability in a locus-specific manner[2].However, there is currently no published evidence for specific biological function attributed to C12orf42-AS1 itself.

Disease associations

Other (no current evidence linking C12orf42-AS1 to a specific disease)Antisense RNAs as a class are increasingly investigated in cancer and epigenetic diseases, but C12orf42-AS1 has no direct association reported[2].

Safety considerations

None notable or reported; long non-coding RNAs as a class pose challenges in drug targeting (off-target effects, cytotoxicity), but C12orf42-AS1 has not been specifically targeted[2].

Beyond the preview

Go deeper on C12orf42 antisense RNA 1 (C12orf42-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C12orf42 antisense RNA 1 (C12orf42-AS1).

Explore the full profile